Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

Cutting Edge: Autocrine TGF-  Sustains Default Tolerogenesis by IDO-Competent Dendritic Cells

(2014) M. L. Belladonna et al.   JOURNAL OF IMMUNOLOGY

IDO2 Is a Critical Mediator of Autoantibody Production and Inflammatory Pathogenesis in a Mouse Model of Autoimmune Arthritis

(2014) L. M. F. Merlo et al.   JOURNAL OF IMMUNOLOGY

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

(2013) T. Z. Iversen et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Methylation signature of lymph node metastases in breast cancer patients

(2012) Zeinab Barekati et al.   BMC CANCER

Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase

(2012) Mee Young Chang et al.   CANCER BIOLOGY & THERAPY

Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors

(2012) Elizabeth S. McKenna et al.   CELL CYCLE

Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation

(2012) Vera Levina et al.   Clinical & Developmental Immunology

Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases

(2012) G. C. Prendergast et al.   CURRENT MEDICINAL CHEMISTRY

Indoleamine 2,3-dioxygenase: From catalyst to signaling function

(2012) Francesca Fallarino et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Amino acid catabolism: a pivotal regulator of innate and adaptive immunity

(2012) Tracy L. McGaha et al.   IMMUNOLOGICAL REVIEWS

The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation

(2012) Olga Anczuków et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Tumor suppressor TSC1 is critical for T-cell anergy

(2012) D.-L. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

A perspective on new immune adjuvant principles

(2012) George C. Prendergast et al.   OncoImmunology

Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future

(2012) George C. Prendergast   OncoImmunology

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

(2012) Richard Metz et al.   OncoImmunology

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

Splicing Factor hnRNP A2/B1 Regulates Tumor Suppressor Gene Splicing and Is an Oncogenic Driver in Glioblastoma

(2011) R. Golan-Gerstl et al.   CANCER RESEARCH

Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

(2011) R. B. Sorensen et al.   CANCER RESEARCH

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells

(2011) Huai-Chia Chuang et al.   NATURE IMMUNOLOGY

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

(2011) Maria T Pallotta et al.   NATURE IMMUNOLOGY

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing a Blood-Based Test in Breast Cancer

(2011) Ramin Radpour et al.   PLoS One

Towards a Genetic Definition of Cancer-Associated Inflammation

(2010) George C. Prendergast et al.   AMERICAN JOURNAL OF PATHOLOGY

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

(2010) R. B. Sorensen et al.   BLOOD

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

(2010) Alexander J. Muller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate

(2010) A. J. Muller et al.   CANCER RESEARCH

mTOR signalling and metabolic regulation of T cell differentiation

(2010) Christian Peter et al.   CURRENT OPINION IN IMMUNOLOGY

An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

(2010) J. D. Mezrich et al.   JOURNAL OF IMMUNOLOGY

Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy

(2009) X. Liu et al.   CURRENT CANCER DRUG TARGETS

The aryl hydrocarbon receptor: a perspective on potential roles in the immune system

(2009) Emily A. Stevens et al.   IMMUNOLOGY

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity

(2009) G. N. Scott et al.   JOURNAL OF IMMUNOLOGY

Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array

(2009) R Radpour et al.   ONCOGENE

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase

(2009) Rikke Bæk Sørensen et al.   PLoS One

Infectious tolerance via the consumption of essential amino acids and mTOR signaling

(2009) S. P. Cobbold et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-β and kynurenines as the key to infectious tolerance

(2009) Maria L. Belladonna et al.   TRENDS IN MOLECULAR MEDICINE

Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase

(2008) Christoph F.A. Vogel et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

(2008) Stefan Löb et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Twelve immunotherapy drugs that could cure cancers

(2008) Martin A. ‘Mac’ Cheever   IMMUNOLOGICAL REVIEWS

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

(2008) Jessica B. Katz et al.   IMMUNOLOGICAL REVIEWS

Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness

(2008) Gerald Willimsky et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells

(2008) Sung Yong Lee et al.   JOURNAL OF IMMUNOTHERAPY

Immune escape as a fundamental trait of cancer: focus on IDO

(2008) G C Prendergast   ONCOGENE

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

(2008) A. J. Muller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA